Mark Gibbs, MD
Sports Medicine · Paris, TXNPI 1568685873
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,111 of the $3,412 with a category attached, or 61.9%. Pylant Medical accounts for 63.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $1,336 and has fallen 60.1% since, to $533 in 2025.
Across 41 payments — averaging $83.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pylant Medical$2K
- Johnson & Johnson$426
- Smith+Nephew$313
- Acumed LLC$131
- Pacira Therapeutics, Inc.$110
- Zimmer Biomet$43
- plus $231 from 10 others
What the payments were for
- Food & beverage$1,30138%
- Education$2,11162%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pylant Medical | 4 | $2,159 |
| Johnson & Johnson(2 entities) | 10 | $426 |
| Smith+Nephew | 5 | $313 |
| Acumed LLC | 1 | $131 |
| Pacira Therapeutics, Inc. | 6 | $110 |
| Zimmer Biomet | 1 | $43 |
| Vertex | 2 | $41 |
| Integra Lifesciences Corporation | 2 | $38 |
| Bioventus LLC | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Stryker | 1 | $22 |
| Amgen | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Medtronic | 1 | $13 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,412 in reported general payments places this provider in the 55th percentile of 437 sports medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 143 | $1,234 |
| Celecoxib | 52 | $577 |
| Oxycodone Hcl | 57 | $427 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $410 |
| Meloxicam | 156 | $374 |
| Doxycycline Hyclate | 17 | $203 |
| Methylprednisolone | 24 | $152 |
| Tramadol Hcl | 44 | $133 |
| Pregabalin | 16 | $132 |
| Mupirocin | 12 | $102 |
| Amoxicillin | 24 | $26 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Paris
- Thomas DeberardinoSan Antonio$3.5M
- Robert ScheinbergDallas$2.2M
- Walter LoweHouston$1.4M
- Reed BartzSunnyvale$1.2M
- James GregoryHouston$565K
- John McDonaldAustin$499K
- James McKinleyTyler$305K
- Kelechi OkorohaDallas$297K
- Leon PaulosPearland$289K
- Marc LabbeThe Woodlands$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.